SCHEMBL2806084

SCHEMBL2806084

CNC(=O)c1ccc(-c2ccc(F)nc2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 1/20 0.58
MKNK2 Q9HBH9 1/20 0.58
HDAC6 Q9UBN7 2/20 0.47
HDAC2 Q92769 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
BAZ2B Q9UIF8 1/20 0.46
RPS6KA3 P51812 1/20 0.46
MCHR1 Q99705 1/20 0.46
PLK1 P53350 5/20 0.45
MMP2 P08253 1/20 0.45
MMP9 P14780 1/20 0.45
MMP13 P45452 1/20 0.45
HDAC4 P56524 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CHEK2 O96017 1/20 0.44
KCNQ3 O43525 1/20 0.43
KCNQ2 O43526 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19983089 0.86 BAZ2B (0.56) MKNK1MKNK2HDAC6HDAC2HDAC8
SCHEMBL483725 0.81 HSD17B1 (0.52) MKNK1MKNK2RPS6KA3MCHR1MMP2
SCHEMBL16198923 0.80 HDAC6 (0.70) MKNK1MKNK2HDAC6HDAC2HDAC8
SCHEMBL14115137 0.80 HDAC6 (0.70) MKNK1MKNK2HDAC6HDAC2HDAC8
SCHEMBL2042090 0.79 BCL2L1 (0.59) MKNK1MKNK2RPS6KA3TSHR
SCHEMBL29788190 0.79 BCL2L1 (0.59) MKNK1MKNK2RPS6KA3TSHR
SCHEMBL4140631 0.79 MKNK1 (0.56) MKNK1MKNK2HDAC6HDAC2HDAC8
SCHEMBL14815487 0.78 MKNK1 (0.55) MKNK1MKNK2HDAC6HDAC2HDAC8
SCHEMBL12875869 0.78 MKNK1 (0.68) MKNK1MKNK2HDAC6PLK1HPGD
SCHEMBL22575207 0.77 CSNK2A1 (0.52) MMP2MMP9HDAC4HPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 US disclosed
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 US disclosed
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS INCYTE CORPORATION 2013-11-07 US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 US disclosed
US-8481732-B2 Substituted heterocyclic compounds INCYTE CORPORATION (US) 2013-07-09 US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 US disclosed
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS INCYTE CORPORATION (US) 2010-09-23 US disclosed
WO-2010108059-A1 SUBSTITUTED PYRIMIDINE DERIVATIVES AS ANTAGONISTS OF THE HISTAMINE H4 RECEPTOR INCYTE CORPORATION (US) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130296327-A1 SUBSTITUTED HETEROCYLIC COMPOUNDS HRH4, HRH2, HRH1 MKNK1 3042/4885MKNK2 2789/4885HDAC6 119/4885
US-20100240671-A1 SUBSTITUTED HETEROCYCLIC COMPOUNDS HRH4, HRH2, HRH1 MKNK1 2737/4885MKNK2 2566/4885HDAC6 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.